Skip NavigationSkip to Content

Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: Possible role of the prolonged half-life of the immunogen

  1. Author:
    Zhang, M. Y.
    Wang, Y. P.
    Mankowski, M. K.
    Ptak, R. G.
    Dimitrov, D. S.
  2. Author Address

    Zhang, Mei-Yun, Wang, Yanping, Dimitrov, Dimiter S.] NCI Frederick, Ctr Canc Res, Nanobiol Program, CCR,NIH, Frederick, MD 21702 USA. [Zhang, Mei-Yun, Wang, Yanping] NCI Frederick, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA. [Mankowski, Marie K.; Ptak, Roger G.] So Res Inst, Frederick, MD 21701 USA.
    1. Year: 2009
  1. Journal: Vaccine
    1. 27
    2. 6
    3. Pages: 857-863
  2. Type of Article: Article
  1. Abstract:

    The elicitation of broadly cross-reactive HIV-1 neutralizing antibodies in humans remains a major challenge in developing a viable AIDS vaccine. We hypothesized that prolonged exposure to candidate vaccine immunogens Could enhance the elicitation of such antibodies. In all attempt to develop HIV-1 vaccine immunogens with prolonged half-lives and increased stability, we constructed a fusion protein, gp41Fc, in was fused to a human IgG(1) Fc.Gp41Fc is stable in solution, retains its antigenic truncated HIV-1 gp41(89.6) genic structure and is highly immunogenic in rabbits. The serum titers reached 1: 102,400 for the gp41Fc and 1:5,120 for gp140(89.6). Rabbit IgG neutralized diverse HIV-1 isolates and HIV-2, and the neutralization activity was attributed to gp41-specific IgG. The concentration of the gp41Fc in the serum correlated with the neutralization activity of rabbit IgG which recognized mostly con formation-independent epitopes oil gp41 and predominantly bound to peptides derived from the gp41 immunodominant loop region. These results Suggest that the prolonged half-life of gp41Fc in the serum may enhance the generation of cross-reactive neutralizing antibodies. Further research is needed to confirm and extend these results which may have implications for the development of vaccine immunogens with enhanced capability to elicit cross-reactive HIV-1-neutralizing antibodies. (C) 2008 Elsevier Ltd. All rights reserved.

    See More

External Sources

  1. PMID: 19084043

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel